Global Source Ventures

SelectION is a clinical-stage biopharmaceutical company focused on developing innovative peptide therapies for autoimmune diseases and certain cancer indications. The company utilizes a specialized technology platform that targets autoreactive, chronically activated T cells through the creation of selective peptide blockers for ion channels associated with these conditions. This approach aims to functionally inhibit and eliminate disease-related T cells while preserving the protective immune response. By optimizing target selectivity, SelectION seeks to develop therapeutics that offer significantly improved efficacy and safety profiles, ultimately providing healthcare institutions with effective treatment options for pain management and oncology.

Oncternal Therapeutics is a clinical-stage oncology company focused on developing innovative therapies for a range of cancers, including both rare and common types. The company has a diverse clinical pipeline featuring several promising candidates, including zilovertamab, a humanized monoclonal antibody targeting ROR1, and ONCT-216, a small molecule designed to inhibit ETS-family transcription factor oncoproteins. Additionally, Oncternal is advancing ONCT-808, a CAR-T product targeting ROR1, and ONCT-534, a dual-action androgen receptor inhibitor aimed at treating castration-resistant prostate cancer. By employing a variety of therapeutic strategies, including antibodies, antibody-drug conjugates, small molecules, and CAR-T technologies, Oncternal Therapeutics seeks to address significant unmet medical needs in oncology through highly targeted treatments.

Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative treatments for patients in hospital settings. The company's primary focus is on ZOLYD, an investigational injectable antibiotic designed to address serious and life-threatening infections, including those caused by multi-drug resistant gram-negative and gram-positive bacteria. Incorporated in 2013, Zavante aims to enhance patient outcomes through its novel therapeutic approaches. As of July 2018, it operates as a subsidiary of Nabriva Therapeutics plc.